Medimmune stops arthritis and psoriasis trials

By Staff Writers
Tuesday, 31 August, 2004

Maryland-based MedImmune has halted the clinical trials of its Vitaxin drug for rheumatoid arthritis and psoriasis, blaming a lack of benefits seen with the experimental treatment.

The drug maker said no safety issues came up during the trial. It will continue to study the compound to treat cancer.

Anti-inflammatory drug may help treat alcohol use disorder

A drug that is already FDA-approved for treating inflammatory conditions may help reduce both...

Osteoarthritis study uncovers new genetic links, drug targets

The genome-wide association study (GWAS) uncovered over 900 genetic associations, more than 500...

How brain cells are affected by Tourette syndrome

US researchers have conducted a cell-by-cell analysis of brain tissue from individuals with...

Content from other channels on our network

Victoria's Q3 median ED wait times the lowest on record

'Enhanced cleaning' cuts hospital-acquired infections by one-third

Perioperative nurses take on surgical escape room

Biophilic healing: expanded Latrobe Regional Hospital, Traralgon

Nominations open for 2025 National Palliative Care Awards

Tallawang Solar Hybrid project secures access rights

CSIRO announces ON Accelerate project teams

SEW Water Saver App recognised as awards finalist

How AI-powered bushfire detection can protect forests and communities

Industrias partners with Microgrid Power to maintain solar

Long-duration battery technologies crucial for a clean energy future: UNSW

Bega Group to close Victorian cheese factory

Engineers Australia appoints new Chief Engineer

South Australia’s exports to the EU hit $1 billion

Incat launches the world’s largest battery‍-‍electric ship